The 2026 Biologics Contract Manufacturing Report
Access the latest edition of our signature Biologics Contract Manufacturing Report to examine how specialized manufacturing capabilities, investment, and M&A are reshaping the global biologics contract manufacturing landscape.
The 2026 report examines how biologics outsourcing continues to evolve as sponsors seek manufacturing partners with differentiated expertise, regulatory sophistication, and modality-specific capabilities.
Preview Our Biologics CDMO Market Insights
- Biologics CDMO market growth is increasingly concentrated among industry leaders. The ten largest CDMOs now account for 55 percent of total market value.
- Specialized manufacturing capabilities are becoming the primary source of competitive advantage for CDMOs. Fewer than 15 CDMOs worldwide currently offer commercial-scale GLP-1 peptide manufacturing.
-
Capital investment and M&A are increasingly targeting differentiated capabilities rather than additional capacity.
M&A activity rebounded to 29 transactions in 2025, with manufacturing capability central to nearly 80 percent of deals. - Manufacturing investment in biologics CDMOs continues to favor the United States. More than 84 percent of the $13.3 billion in disclosed manufacturing investment was directed to US facilities.
Grab your copy now! The report analyzes global market dynamics, investment trends, M&A activity, and manufacturing capacity across protein biologics, vaccines, and advanced therapies.
The 2026 Biologics Contract Manufacturing Report
Access the latest edition of our signature Biologics Contract Manufacturing Report to examine how specialized manufacturing capabilities, investment, and M&A are reshaping the global biologics contract manufacturing landscape.
The 2026 report examines how biologics outsourcing continues to evolve as sponsors seek manufacturing partners with differentiated expertise, regulatory sophistication, and modality-specific capabilities.
Preview Our Biologics CDMO Market Insights
- Biologics CDMO market growth is increasingly concentrated among industry leaders. The ten largest CDMOs now account for 55 percent of total market value.
- Specialized manufacturing capabilities are becoming the primary source of competitive advantage for CDMOs. Fewer than 15 CDMOs worldwide currently offer commercial-scale GLP-1 peptide manufacturing.
- Capital investment and M&A are increasingly targeting differentiated capabilities rather than additional capacity. M&A activity rebounded to 29 transactions in 2025, with manufacturing capability central to nearly 80 percent of deals.
- Manufacturing investment in biologics CDMOs continues to favor the United States. More than 84 percent of the $13.3 billion in disclosed manufacturing investment was directed to US facilities.
Subscribe to our newsletter for the latest news, events, and thought leadership